Keywords: atrix, plans, file, prostate, cancer, drug, results

Atrix plans to file for prostate cancer drug

Article | 07 December 2000

The results of a Phase III study of a one-month, 7.5mg depot formulationof the luteinizing hormone-releasing hormone antagonist leuprolide acetate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Striant

Testosterone

Testoderm

Eligard

Leuprolide Acetate

Go to drug listing